For the Inventor, By the Inventor

Enter assignee name

Mercian Corporation

Calculating rank

USPTO Granted Patents = 40

% Expired Patents = 32.5

EPO Patents = 6

Trademarks = 3

Forward Citations = 151

Loading Chart...

Loading Chart...

101 inventors (with patents filed for the assignee):

Takeo Yoshioka (21 out of 41 patents)

Takashi Nakashima (13 out of 22 patents)

Kunio Isshiki (10 out of 16 patents)

4. Toshio Tsuchida (9 out of 15 patents)

5. Kazuyuki Dobashi (7 out of 9 patents)

6. Rokuro Okamoto (6 out of 20 patents)

7. Mitsuo Nagai (5 out of 28 patents)

8. Tomohiro Sameshima (5 out of 7 patents)

9. Takao Narita (5 out of 5 patents)

10. Hiroshi Tone (5 out of 13 patents)

11. Jun Niijima (4 out of 25 patents)

12. Masashi Yoshida (4 out of 9 patents)

13. Yoshihiko Kotake (4 out of 26 patents)

14. Susumu Takeda (4 out of 6 patents)

15. Naoto Kawamura (4 out of 7 patents)

Core Competencies:

Hydroxylation

Macrolide Antibiotics

Physiologically Active Substances

Optically Active Compounds

Dihydropyridine Derivatives

Steroids Production

Antitumor Agents

Crystalline Antibiotics

Gene Encoding Proteins

Cyclodextrin Production

Osteoclast Differentiation Inhibitors

Azetidinone Derivatives

40 patents: Sort by Forward Citations

1. 7932083 - DNA participating in hydroxylation of macrolide compound (2011-04-26),

2. 7893068 - Physiologically active substances (2011-02-22),

3. 7790887 - Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same (2010-09-07),

4. 7745198 - Method of producing macrolide compound (2010-06-29),

5. 7655442 - Method for stabilizing macrolide compounds (2010-02-02),

6. 7619100 - Physiologically active substances (2009-11-17),

7. 7576204 - Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same (2009-08-18),

8. 7256178 - Physiologically active substances (2007-08-14),

9. 7247729 - Method for producing pipecolamide derivative (2007-07-24),

10. 7235388 - Isolated nucleic acid encoding L-lysine: 2-oxoglutaric acid 6-aminotransferase (2007-06-26),

11. 7115412 - Process for the preparation of optically active 7-substituted-3-(2-aminopropyl)indole derivatives and intermediates therefor (2006-10-03),

12. 7060821 - Osteoclast differentiation inhibitors (2006-06-13),

13. 7026352 - Physiologically active substances (2006-04-11),

14. 7022502 - Process for the biological production of L-pipecolic acid (2006-04-04),

15. 6900340 - Preparation of isocoumarin derivatives and intermediates for the synthesis thereof (2005-05-31),

Company Overview

Mercian Corporation, based in Tokyo, specializes in the development and production of advanced macrolide compounds and physiologically active substances. The company focuses on innovative research in heterocyclic macrolides and isocoumarin derivatives, contributing to the field of osteoclast differentiation inhibitors and dihydroxycholesterol. With a commitment to biological production processes, Mercian plays a significant role in the pharmaceutical and biotechnology sectors, enhancing therapeutic options through its cutting-edge technologies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

40 Patents

#933 in Tokyo

#1,980 in Japan

#17,087 in the World

Mercian Corporation

Forward Citations = 151

101 inventors:

Takeo Yoshioka (21 out of 41 patents)

Takashi Nakashima (13 out of 22 patents)

Kunio Isshiki (10 out of 16 patents)

4. Toshio Tsuchida (9 out of 15 patents)

5. Kazuyuki Dobashi (7 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mercian Corporation. Retrieved from https://idiyas.com/company/mercian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…